Home › Gilead Sciences halts drug studies over side effects, death
 

Keywords :   


Gilead Sciences halts drug studies over side effects, death

2016-03-15 23:33:19| Biotech - Topix.net

Biologic drugmaker Gilead Sciences Inc. has halted several patient studies of its cancer drug, Zydelig, because of increased risk of death and serious side effects. The company told The Associated Press the "adverse events" were spotted during an ongoing review of late-stage testing in patients with chronic lymphocytic leukemia, a blood cancer, and patients with relapsed non-Hodgkin's lymphoma, a cancer of the infection-fighting lymphatic system.

Tags: side death effects studies

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05WCC Re-elects Tom Bowtell for Second Term as President, Recognizes Contributions of Andy Doyle
20.05DKSH Extends Distribution Agreement with KRONOS in Asia Pacific
20.05NABC hosts foreign animal disease tabletop exercise
20.05Printed Easy increases capacity by 300% with Durst
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05IMDA launches annual IMDA Awards Competition
20.05Registration opens for FTAs Fall Technical Conference 2024
More »